Stock Scorecard
Stock Summary for NovoCure Ltd (NVCR) - $13.80 as of 1/16/2026 2:13:44 PM EST
Total Score
10 out of 30
Safety Score
24 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for NVCR
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for NVCR
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for NVCR
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for NVCR
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for NVCR (24 out of 100)
| Stock Price Rating (Max of 10) | 5 |
| Historical Stock Price Rating (Max of 10) | 9 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 3 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 4 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for NVCR
Financial Details for NVCR
Company Overview |
|
|---|---|
| Ticker | NVCR |
| Company Name | NovoCure Ltd |
| Country | N/A |
| Description | Novocure Ltd is a pioneering oncology company based in Saint Helier, Jersey, specializing in the development of tumor-treating fields (TTFields) therapy, exemplified by its flagship product, Optune. This innovative technology disrupts the proliferation of cancer cells and is currently approved for treating glioblastoma multiforme and mesothelioma. With a robust pipeline of clinical trials and research commitments, Novocure is dedicated to enhancing its position as a leader in the oncology sector by developing transformative therapies that meet urgent unmet medical needs in cancer treatment, underpinning its potential for significant growth in the evolving healthcare landscape. |
| Sector Name | HEALTHCARE |
| Industry Name | MEDICAL DEVICES |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 2/26/2026 |
Stock Price History |
|
| Last Day Price | 13.80 |
| Price 4 Years Ago | 75.08 |
| Last Day Price Updated | 1/16/2026 2:13:44 PM EST |
| Last Day Volume | 1,412,729 |
| Average Daily Volume | 1,427,651 |
| 52-Week High | 30.78 |
| 52-Week Low | 10.70 |
| Last Price to 52 Week Low | 28.97% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 51.61 |
| Sector PE | 54.65 |
| 5-Year Average PE | -51.42 |
| Free Cash Flow Ratio | 4.48 |
| Industry Free Cash Flow Ratio | 26.14 |
| Sector Free Cash Flow Ratio | 28.78 |
| Current Ratio Most Recent Quarter | 1.55 |
| Total Cash Per Share | 3.08 |
| Book Value Per Share Most Recent Quarter | 3.05 |
| Price to Book Ratio | 4.24 |
| Industry Price to Book Ratio | 3.75 |
| Sector Price to Book Ratio | 43.34 |
| Price to Sales Ratio Twelve Trailing Months | 2.25 |
| Industry Price to Sales Ratio Twelve Trailing Months | 4.01 |
| Sector Price to Sales Ratio Twelve Trailing Months | 19.82 |
| Analyst Buy Ratings | 4 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 111,982,000 |
| Market Capitalization | 1,545,351,600 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | -6.00% |
| Annual Earnings Growth | 18.55% |
| Reported EPS 12 Trailing Months | -1.61 |
| Reported EPS Past Year | -1.00 |
| Reported EPS Prior Year | -1.56 |
| Net Income Twelve Trailing Months | -177,650,000 |
| Net Income Past Year | -168,627,000 |
| Net Income Prior Year | -207,043,000 |
| Quarterly Revenue Growth YOY | 7.80% |
| 5-Year Revenue Growth | 11.49% |
| Operating Margin Twelve Trailing Months | -21.50% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 344,638,000 |
| Total Cash Past Year | 163,767,000 |
| Total Cash Prior Year | 240,821,000 |
| Net Cash Position Most Recent Quarter | 149,999,000 |
| Net Cash Position Past Year | 66,467,000 |
| Long Term Debt Past Year | 97,300,000 |
| Long Term Debt Prior Year | 568,822,000 |
| Total Debt Most Recent Quarter | 194,639,000 |
| Equity to Debt Ratio Past Year | 0.79 |
| Equity to Debt Ratio Most Recent Quarter | 0.64 |
| Total Stockholder Equity Past Year | 360,179,000 |
| Total Stockholder Equity Prior Year | 362,496,000 |
| Total Stockholder Equity Most Recent Quarter | 341,333,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -65,172,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.58 |
| Free Cash Flow Past Year | -69,224,000 |
| Free Cash Flow Prior Year | -100,429,000 |
Options |
|
| Put/Call Ratio | 3.87 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.35 |
| MACD Signal | 0.39 |
| 20-Day Bollinger Lower Band | 11.07 |
| 20-Day Bollinger Middle Band | 12.92 |
| 20-Day Bollinger Upper Band | 14.77 |
| Beta | 0.82 |
| RSI | 53.61 |
| 50-Day SMA | 15.69 |
| 150-Day SMA | 23.20 |
| 200-Day SMA | 37.00 |
System |
|
| Modified | 1/16/2026 11:52:51 PM EST |